FILE:LH/LH-8K-20070215074505.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company dated February 15, 2007.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
8-K Filed February 15, 2007
1
 
            
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2005, and subsequent SEC filings, and will be available in the Company's Form 10-K for the year ended December 31, 2006, when filed.
2
 
The Clinical Laboratory Testing Market > $40 - $50 billion Annually
Industry CAGR of 5% - 7%
Market segments:
Routine ~ $30 - $35 billion
Esoteric ~ $4 - $5 billion
Anatomic pathology ~ $6 - $10 billion
Growth opportunities:
Consolidation
Esoteric and anatomic pathology testing
Hospital outpatient and outreach
Source:    Company estimates, industry reports and 2005 revenue for LabCorp.
3
 
Industry Profile
Integral to quality healthcare
Screening for and early diagnosis of disease leads to improved outcomes
Monitoring of treatment effectiveness and disease recurrence
Correct therapy decisions based on known genetic markers
Cost effectiveness
Cutting-edge technologies
Influences 70% - 80% of healthcare decisions
Rigorous quality standards
4
 
Profile of LabCorp
The leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
Offers the broadest range of clinical and anatomic pathology services to aid clinicians in diagnosis, monitoring, prediction and prevention of disease
Conducts > 270 million tests annually
Connectivity with physicians offices
90% of results delivered electronically
70% of tests ordered electronically
5
 
Profile of LabCorp
More than 25,000 employees nationwide
6,200 phlebotomists
2,600 couriers
700 MDs and PhDs
1,700 conveniently located patient service centers
Rigorously monitored, industry-leading quality and service metrics
Highest quality, CAP inspected and CLIA certified laboratories
6
 
Primary Testing Locations
Primary LabCorp Testing Locations
Corporate Headquarters
Burlington, NC
7
 
What is LabCorp?
Clinical Pathology
Medical
Testing
Services
Esoteric
Testing
Genomics
Anatomic Pathology
8
 
Strategic Focus Areas
Scientific
Leadership
Managed
Care
Customer
Focus
Cancer diagnostics and monitoring
Advanced cardiovascular disease testing
Quality and service driven culture
Continuous enhancements in customer connectivity
First-time problem resolution
Advancement through acquisitions and licensing
Partner to control high cost leakage
Lab data enables better treatment and outcomes
Recognize
v
alue of lab services through appropriate pricing
9
 
UnitedHealthcare
Exclusive national laboratory provider
$3 billion in additional revenue over a 10- year contract term
EBITDA margins at least equal to our existing, industry-leading level
Revenue will ramp during 2007 and later years
Transition payments capped at $200 million
10
 
UnitedHealthcare
Phase 1  exclusivity in mature markets (MAMSI, Neighborhood, Pacificare Colorado), network manager for Oxford, plus sole national laboratory in all other markets
Phase 2  establish additional networks
Phase 3  use networks and standardized data to enhance development of evidence- based medicine
11
 
UnitedHealthcare as a Growth Driver
United opportunity:
Mature markets
Direct business
Indirect business
Networks
Over 420 new patient access points:
Innovative Duane Reade agreement
400 other locations opened since 10/3/06
Available to
all
patients
New employees trained and on-board prior to 1/1/07  lab techs, phlebotomists, sales reps, couriers.
Primary connectivity with more physician offices in key markets
12
 
Revenue Growth Drivers
Managed Care
Partner of choice for major managed care organizations
Recognition of value from standardized lab data
Breadth of test menu, quality, convenience
Cancer diagnostics
Anatomic pathology - $6 - $10 billion fragmented market
Treatment decisions/monitoring
Recurrence testing
Cardiovascular disease
Lab testing is foundation for determining need for imaging, invasive procedures, pharmaceutical treatments
VAP, NMR, high-sensitivity CRP
13
 
EBITDA Margin Growth Drivers
Increased volumes through fixed-cost infrastructure
Larger number of esoteric tests offered, more esoteric tests ordered
Further operational efficiencies
Increase automation in pre-analytic processes
Logistics / route structure optimization
Supply chain management
Improvement in collections / bad debt
14
 
LabCorp's Investment and Performance Fundamentals
Industry-leading EBITDA margins
Significant free cash flow
Focus on returning value to shareholders
Strategic acquisitions
Organic growth opportunities
Share repurchase
Flexibility for future growth opportunities
15
 
Five-Year Revenue and EPS Trend
Revenue CAGR of 9%   -   Diluted EPS CAGR of 19%
(1)
(1)
Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non- recurring investment loss.
(2)
Excluding the $0.07 per diluted share impact in 2006 of restructuring and other special charges, and the $0.10 per diluted share impact in 2006 of adoption of SFAS 123(R).
16
 
Five-Year OCF and EBITDA Margin Trend
OCF CAGR of 9%   -   EBITDA Margin Growth of 420 bps
(1)
Includes approximately $50 million of benefit from one-time tax credits recorded in 2003.
(2)
Excluding the impact in 2005 of restructuring and other special charges and a non-recurring investment loss.
(3)
Excluding the impact in 2006 of restructuring and other special charges and of the adoption of SFAS 123(R).
17
 
Fourth Quarter Results
(in millions, except per share data)
(1) Excludes restructuring and other special charges of  $6.9 million and $7.7 million, recorded by the Company in the fourth quarters of 2005 and 2006, respectively, and $6.4 million of stock compensation expense recorded by the Company in the fourth quarter of 2006 from the adoption of SFAS 123(R).
(2) Excludes the $0.03 and $0.04 per diluted share impact of the restructuring and other special charges recorded in the fourth quarters of 2005 and 2006, respectively, and the $0.03 per diluted share impact in the fourth quarter of 2006 from the adoption of SFAS 123(R).
18
 
Full-Year Results
(in millions, except per share data)
(1) For 2005, EBITDA excludes restructuring and other special charges of  $16.9 million and a non-recurring investment loss of $3.1 million.  For 2006, EBITDA excludes restructuring and other special charges of $13.4 million, and $23.3 million of stock compensation expense from the adoption of SFAS 123(R).
(2) For 2005, Diluted EPS excludes the $0.09 per diluted share impact of restructuring and other special charges and the non-recurring investment loss recorded in 2005.  For 2006, Diluted EPS excludes the $0.06 per diluted share impact of restructuring and other special charges, and the $0.11 per diluted share impact from the adoption of SFAS 123(R).
19
 
2006 Full-Year Financial Achievements
Diluted EPS of $3.41
(1)
EBITDA margin of 26.7% of sales
(2)
Operating cash flow of $632.3 million
Increased revenues 7.9% (3.7% volume; 4.2% price)
Repurchased approximately $435 million of LabCorp stock
(1)
Excludes the $0.06 per diluted share impact of the restructuring and other special charges recorded in 2006, and the $0.11 per diluted share impact of the required change in accounting for stock based compensation adopted in 2006.
(2)
Based on EBITDA of $959.0 million, excluding the $13.4 million impact of restructuring and other special charges and the $23.3 million impact of the change in accounting for stock based compensation adopted in 2006.
20
 
Revenue by Payer  2006
(in millions)
21
 
Revenue by Business Area  2006
(in millions)
22
 
Revenue Mix by Business Area
(in millions)
23
 
Revenue by Payer  2006
(in millions, except PPA)
24
 
Revenue Mix by Business Area
(in millions, except PPA)
25
 
2007 Financial Guidance
Excluding the impact of any share repurchase activity after December 31, 2006, guidance for 2007 is as follows:
Net sales growth of approximately 11 to 13% compared to 2006
EBITDA margins of 26.4% to 26.8% of net sales
Diluted EPS in the range of $3.93 to $4.09
Operating cash flow of between $690 and $710 million, excluding any transition payments related to the Company's agreement with UnitedHealthcare
Capital expenditures of between $110 and $120 million, excluding any additional capital expenditures related to the Company's agreement with UnitedHealthcare
Net interest expense of approximately $46 million
Bad debt rate of approximately 4.8% of net sales
26
 
Reconciliation of Non-GAAP Financial Measures
($ in millions)
27
 
Supplemental Financial Information
28
 


